1-2 of 2
Yue Ren
Close
Sort by
Journal Articles

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Clinical Trials & Observations
Inhye E. Ahn, Danielle M. Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A. Walker, Robert Black, Josie Montegaard, Alvaro Alencar, Leyla Shune, Mohammad Omaira, Caron A. Jacobson, Philippe Armand, Samuel Y. Ng, Jennifer Crombie, David C. Fisher, Ann S. LaCasce, Jon Arnason, Ephraim P. Hochberg, Ronald W. Takvorian, Jeremy S. Abramson, Jennifer R. Brown, Matthew S. Davids
Journal: Blood Advances
Blood Adv (2024) 8 (4): 832–841.
https://doi.org/10.1182/bloodadvances.2023011574
Published: 2024
Includes: Supplemental data
Journal Articles

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

Aishath Naeem, Filippo Utro, Qing Wang, Justin Cha, Mauno Vihinen, Stephen Martindale, Yinglu Zhou, Yue Ren, Svitlana Tyekucheva, Annette S. Kim, Stacey M. Fernandes, Gordon Saksena, Kahn Rhrissorrakrai, Chaya Levovitz, Brian P. Danysh, Kara Slowik, Raquel A. Jacobs, Matthew S. Davids, James A. Lederer, Rula Zain, C. I. Edvard Smith, Ignaty Leshchiner, Laxmi Parida, Gad Getz, Jennifer R. Brown
Journal: Blood Advances
Blood Adv (2023) 7 (9): 1929–1943.
https://doi.org/10.1182/bloodadvances.2022008447
Published: 2023
Includes: Supplemental data